Merck Sharp Dohme Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MERCK SHARP DOHME, and what generic alternatives to MERCK SHARP DOHME drugs are available?
MERCK SHARP DOHME has twenty-three approved drugs.
There are twenty-five US patents protecting MERCK SHARP DOHME drugs.
There are six hundred and ninety patent family members on MERCK SHARP DOHME drugs in sixty-three countries and one hundred and twenty-seven supplementary protection certificates in nineteen countries.
Summary for Merck Sharp Dohme
International Patents: | 690 |
US Patents: | 25 |
Tradenames: | 19 |
Ingredients: | 19 |
NDAs: | 23 |
Drugs and US Patents for Merck Sharp Dohme
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Merck Sharp Dohme | PREVYMIS | letermovir | TABLET;ORAL | 209939-001 | Nov 8, 2017 | RX | Yes | No | 8,513,255 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Merck Sharp Dohme | PREVYMIS | letermovir | SOLUTION;INTRAVENOUS | 209940-002 | Nov 8, 2017 | RX | Yes | Yes | 10,603,384 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Merck Sharp Dohme | VERQUVO | vericiguat | TABLET;ORAL | 214377-003 | Jan 19, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Merck Sharp Dohme | TEMODAR | temozolomide | CAPSULE;ORAL | 021029-003 | Aug 11, 1999 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Merck Sharp Dohme | REBETOL | ribavirin | CAPSULE;ORAL | 020903-001 | Jun 3, 1998 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Merck Sharp Dohme | BELSOMRA | suvorexant | TABLET;ORAL | 204569-001 | Aug 13, 2014 | RX | Yes | No | 10,098,892 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Merck Sharp Dohme
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Merck Sharp Dohme | JUVISYNC | simvastatin; sitagliptin phosphate | TABLET;ORAL | 202343-003 | Oct 7, 2011 | 6,890,898 | ⤷ Try a Trial |
Merck Sharp Dohme | REBETOL | ribavirin | CAPSULE;ORAL | 020903-001 | Jun 3, 1998 | 6,524,570*PED | ⤷ Try a Trial |
Merck Sharp Dohme | JANUVIA | sitagliptin phosphate | TABLET;ORAL | 021995-001 | Oct 16, 2006 | 6,303,661 | ⤷ Try a Trial |
Merck Sharp Dohme | JANUVIA | sitagliptin phosphate | TABLET;ORAL | 021995-001 | Oct 16, 2006 | 6,890,898 | ⤷ Try a Trial |
Merck Sharp Dohme | DUTREBIS | lamivudine; raltegravir potassium | TABLET;ORAL | 206510-001 | Feb 6, 2015 | 7,217,713*PED | ⤷ Try a Trial |
Merck Sharp Dohme | REBETOL | ribavirin | CAPSULE;ORAL | 020903-002 | Jul 25, 2001 | 6,524,570*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MERCK SHARP DOHME drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Orally Disintegrating Tablets | 2.5 mg and 5 mg | ➤ Subscribe | 2006-06-21 |
➤ Subscribe | Tablets | 100 mg/10 mg and 100 mg/40 mg | ➤ Subscribe | 2012-06-19 |
➤ Subscribe | Tablets | 50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg | ➤ Subscribe | 2012-11-06 |
➤ Subscribe | Capsules | 140 mg and 180 mg | ➤ Subscribe | 2008-03-24 |
➤ Subscribe | Delayed-release Tablets | 100 mg | ➤ Subscribe | 2014-06-16 |
➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2006-06-21 |
➤ Subscribe | Tablets | 25 mg, 50 mg and 100 mg | ➤ Subscribe | 2010-10-18 |
➤ Subscribe | Tablets | 100 mg/10 mg and 100 mg/40 mg | ➤ Subscribe | 2012-06-25 |
➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2011-02-28 |
➤ Subscribe | Injection | 18 mg/mL, 16.7 mL vials | ➤ Subscribe | 2015-11-24 |
International Patents for Merck Sharp Dohme Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Morocco | 31016 | ⤷ Try a Trial |
Hungary | S1800028 | ⤷ Try a Trial |
Taiwan | I631123 | ⤷ Try a Trial |
European Patent Office | 3556350 | ⤷ Try a Trial |
Slovenia | 2896617 | ⤷ Try a Trial |
South Korea | 101350420 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Merck Sharp Dohme Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1622880 | LUC00070 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: LETERMOVIR; AUTHORISATION NUMBER AND DATE: EU71/17/1245 20180110 |
1385870 | 1190037-0 | Sweden | ⤷ Try a Trial | PRODUCT NAME: BOCEPREVIR ELLER EN ENANTIOMER, STEREOISOMER, ROTAMER, TAUTOMER ELLER RACEMAT AV NAEMNDA FOERENING ELLER ETT FARMACEUTISKT GODTAGBART SALT ELLER SOLVAT AV NAEMNDA FOERENING; REG. NO/DATE: EU/1/11/704/001 20110718 |
2576547 | LUC00221 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: VERICIGUAT ET SES SELS, SOLVATES ET SOLVATES DES SELS; AUTHORISATION NUMBER AND DATE: EU/1/21/1561 20210720 |
1412357 | 77 5006-2008 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: SITAGLIPTIN A METFORMIN; NAT. REG.NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REG.:CH 58450 01-03 20080408 |
1412357 | CA 2008 00035 | Denmark | ⤷ Try a Trial | PRODUCT NAME: SITAGLIPTIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER MONOPHOSPHAT, METFORMIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER HYDROCHLORID |
0720599 | 26/2005 | Austria | ⤷ Try a Trial | PRODUCT NAME: EZETIMIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON KOMBINIERT MIT SIMVASTATIN; NAT. REGISTRATION NO/DATE: 1-25673 - 1-25676 20041228; FIRST REGISTRATION: DE 58874.00.00 - 58874.03.00; 58878.00.00 - 20040402 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.